PubMed:1820200 JSONTXT

{"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":1662,"end":1681},"obj":"https://glytoucan.org/Structures/Glycans/G64581RP"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":1662,"end":1681},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G64581RP"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":149},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":150,"end":472},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":473,"end":643},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":644,"end":1724},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":1725,"end":2065},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":149},"obj":"Sentence"},{"id":"T2","span":{"begin":150,"end":472},"obj":"Sentence"},{"id":"T3","span":{"begin":473,"end":643},"obj":"Sentence"},{"id":"T4","span":{"begin":644,"end":1724},"obj":"Sentence"},{"id":"T5","span":{"begin":1725,"end":2065},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":149},"obj":"Sentence"},{"id":"T2","span":{"begin":150,"end":472},"obj":"Sentence"},{"id":"T3","span":{"begin":473,"end":643},"obj":"Sentence"},{"id":"T4","span":{"begin":644,"end":1724},"obj":"Sentence"},{"id":"T5","span":{"begin":1725,"end":2065},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":1662,"end":1681},"obj":"https://glytoucan.org/Structures/Glycans/G64581RP"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlycoBiology-GDGDB","denotations":[{"id":"_T1","span":{"begin":1988,"end":2005},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00008"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":39,"end":48},"obj":"FMAID:188332"},{"id":"_T2","span":{"begin":39,"end":48},"obj":"FMAID:80224"},{"id":"_T3","span":{"begin":49,"end":62},"obj":"FMAID:83362"},{"id":"_T4","span":{"begin":49,"end":62},"obj":"FMAID:83100"},{"id":"_T5","span":{"begin":49,"end":62},"obj":"FMAID:197647"},{"id":"_T6","span":{"begin":49,"end":62},"obj":"FMAID:197370"},{"id":"_T7","span":{"begin":87,"end":100},"obj":"FMAID:196778"},{"id":"_T8","span":{"begin":87,"end":100},"obj":"FMAID:82784"},{"id":"_T9","span":{"begin":150,"end":163},"obj":"FMAID:196778"},{"id":"_T10","span":{"begin":150,"end":163},"obj":"FMAID:82784"},{"id":"_T11","span":{"begin":231,"end":243},"obj":"FMAID:167256"},{"id":"_T12","span":{"begin":231,"end":243},"obj":"FMAID:62925"},{"id":"_T13","span":{"begin":244,"end":251},"obj":"FMAID:12278"},{"id":"_T14","span":{"begin":244,"end":251},"obj":"FMAID:101015"},{"id":"_T15","span":{"begin":258,"end":267},"obj":"FMAID:188332"},{"id":"_T16","span":{"begin":258,"end":267},"obj":"FMAID:80224"},{"id":"_T17","span":{"begin":268,"end":281},"obj":"FMAID:197370"},{"id":"_T18","span":{"begin":268,"end":281},"obj":"FMAID:197647"},{"id":"_T19","span":{"begin":268,"end":281},"obj":"FMAID:83362"},{"id":"_T20","span":{"begin":268,"end":281},"obj":"FMAID:83100"},{"id":"_T21","span":{"begin":540,"end":550},"obj":"FMAID:82739"},{"id":"_T22","span":{"begin":540,"end":550},"obj":"FMAID:196728"},{"id":"_T23","span":{"begin":567,"end":580},"obj":"FMAID:196778"},{"id":"_T24","span":{"begin":567,"end":580},"obj":"FMAID:82784"},{"id":"_T25","span":{"begin":687,"end":703},"obj":"FMAID:82742"},{"id":"_T26","span":{"begin":687,"end":703},"obj":"FMAID:196731"},{"id":"_T27","span":{"begin":1662,"end":1681},"obj":"FMAID:82787"},{"id":"_T28","span":{"begin":1662,"end":1681},"obj":"FMAID:196781"},{"id":"_T29","span":{"begin":1772,"end":1787},"obj":"FMAID:82742"},{"id":"_T30","span":{"begin":1772,"end":1787},"obj":"FMAID:196731"},{"id":"_T31","span":{"begin":1907,"end":1914},"obj":"FMAID:67257"},{"id":"_T32","span":{"begin":1907,"end":1914},"obj":"FMAID:165447"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":795,"end":801},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T2","span":{"begin":810,"end":816},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T3","span":{"begin":850,"end":856},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T4","span":{"begin":865,"end":871},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T5","span":{"begin":933,"end":939},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T6","span":{"begin":948,"end":954},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T7","span":{"begin":990,"end":996},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T8","span":{"begin":1005,"end":1011},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T9","span":{"begin":1031,"end":1037},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T10","span":{"begin":1046,"end":1052},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T11","span":{"begin":1132,"end":1138},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T12","span":{"begin":1147,"end":1153},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T13","span":{"begin":1200,"end":1206},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T14","span":{"begin":1215,"end":1221},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T15","span":{"begin":1260,"end":1266},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T16","span":{"begin":1275,"end":1281},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T17","span":{"begin":1343,"end":1349},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T18","span":{"begin":1358,"end":1364},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T19","span":{"begin":881,"end":883},"obj":"http://www.uniprot.org/uniprot/P10163"},{"id":"T20","span":{"begin":1231,"end":1233},"obj":"http://www.uniprot.org/uniprot/P10163"},{"id":"T21","span":{"begin":1374,"end":1376},"obj":"http://www.uniprot.org/uniprot/P10163"},{"id":"T22","span":{"begin":1453,"end":1455},"obj":"http://www.uniprot.org/uniprot/P10163"},{"id":"T23","span":{"begin":1414,"end":1416},"obj":"http://www.uniprot.org/uniprot/Q8SNA0"},{"id":"T24","span":{"begin":1988,"end":2008},"obj":"http://www.uniprot.org/uniprot/Q16706"},{"id":"T25","span":{"begin":2017,"end":2028},"obj":"http://www.uniprot.org/uniprot/Q99484"},{"id":"T26","span":{"begin":2036,"end":2064},"obj":"http://www.uniprot.org/uniprot/Q9BYC5"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":345,"end":348},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T2","span":{"begin":356,"end":359},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T3","span":{"begin":396,"end":399},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T4","span":{"begin":407,"end":410},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T5","span":{"begin":716,"end":719},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T6","span":{"begin":1418,"end":1421},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T7","span":{"begin":1692,"end":1695},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T8","span":{"begin":1703,"end":1706},"obj":"http://www.uniprot.org/uniprot/Q61024"},{"id":"T9","span":{"begin":1414,"end":1416},"obj":"http://www.uniprot.org/uniprot/P04441"},{"id":"T10","span":{"begin":2017,"end":2028},"obj":"http://www.uniprot.org/uniprot/P38649"},{"id":"T11","span":{"begin":2036,"end":2064},"obj":"http://www.uniprot.org/uniprot/Q9WTS2"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":39,"end":48},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/387016"},{"id":"T2","span":{"begin":217,"end":230},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/1028079"},{"id":"T3","span":{"begin":244,"end":251},"obj":"http://purl.bioontology.org/ontology/STY/T125"},{"id":"T4","span":{"begin":258,"end":267},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/387016"},{"id":"T5","span":{"begin":372,"end":376},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T6","span":{"begin":372,"end":376},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T7","span":{"begin":540,"end":561},"obj":"http://purl.bioontology.org/ontology/STY/T087"},{"id":"T8","span":{"begin":795,"end":799},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T9","span":{"begin":795,"end":799},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T10","span":{"begin":810,"end":814},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T11","span":{"begin":810,"end":814},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T12","span":{"begin":850,"end":854},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T13","span":{"begin":850,"end":854},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T14","span":{"begin":865,"end":869},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T15","span":{"begin":865,"end":869},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T16","span":{"begin":933,"end":937},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T17","span":{"begin":933,"end":937},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T18","span":{"begin":948,"end":952},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T19","span":{"begin":948,"end":952},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T20","span":{"begin":990,"end":994},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T21","span":{"begin":990,"end":994},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T22","span":{"begin":1005,"end":1009},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T23","span":{"begin":1005,"end":1009},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T24","span":{"begin":1031,"end":1035},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T25","span":{"begin":1031,"end":1035},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T26","span":{"begin":1046,"end":1050},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T27","span":{"begin":1046,"end":1050},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T28","span":{"begin":1132,"end":1136},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T29","span":{"begin":1132,"end":1136},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T30","span":{"begin":1147,"end":1151},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T31","span":{"begin":1147,"end":1151},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T32","span":{"begin":1200,"end":1204},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T33","span":{"begin":1200,"end":1204},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T34","span":{"begin":1215,"end":1219},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T35","span":{"begin":1215,"end":1219},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T36","span":{"begin":1260,"end":1264},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T37","span":{"begin":1260,"end":1264},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T38","span":{"begin":1275,"end":1279},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T39","span":{"begin":1275,"end":1279},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T40","span":{"begin":1343,"end":1347},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T41","span":{"begin":1343,"end":1347},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T42","span":{"begin":1358,"end":1362},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T43","span":{"begin":1358,"end":1362},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T44","span":{"begin":1545,"end":1549},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T45","span":{"begin":1545,"end":1549},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":16,"end":29},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T2","span":{"begin":190,"end":203},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T3","span":{"begin":1518,"end":1531},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T4","span":{"begin":329,"end":341},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T5","span":{"begin":380,"end":392},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T6","span":{"begin":418,"end":427},"obj":"http://purl.obolibrary.org/obo/GO_0007586"},{"id":"T7","span":{"begin":1643,"end":1654},"obj":"http://purl.obolibrary.org/obo/GO_0036065"},{"id":"T8","span":{"begin":1988,"end":2008},"obj":"http://purl.obolibrary.org/obo/GO_0004572"},{"id":"T9","span":{"begin":2036,"end":2064},"obj":"http://purl.obolibrary.org/obo/GO_0046921"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":1963,"end":1968},"obj":"http://purl.obolibrary.org/obo/GO_0005794"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":39,"end":48},"obj":"http://purl.obolibrary.org/obo/UBERON_0003124"},{"id":"T2","span":{"begin":258,"end":267},"obj":"http://purl.obolibrary.org/obo/UBERON_0003124"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":33,"end":38},"obj":"http://edamontology.org/topic_2815"},{"id":"T2","span":{"begin":64,"end":83},"obj":"http://edamontology.org/topic_0081"},{"id":"T3","span":{"begin":132,"end":135},"obj":"http://edamontology.org/topic_0593"},{"id":"T4","span":{"begin":132,"end":148},"obj":"http://edamontology.org/topic_0593"},{"id":"T5","span":{"begin":136,"end":148},"obj":"http://edamontology.org/topic_0593"},{"id":"T6","span":{"begin":252,"end":257},"obj":"http://edamontology.org/topic_2815"},{"id":"T7","span":{"begin":540,"end":550},"obj":"http://edamontology.org/topic_0154"},{"id":"T8","span":{"begin":551,"end":561},"obj":"http://edamontology.org/topic_0080"},{"id":"T9","span":{"begin":551,"end":561},"obj":"http://edamontology.org/topic_3168"},{"id":"T10","span":{"begin":626,"end":629},"obj":"http://edamontology.org/topic_0593"},{"id":"T11","span":{"begin":626,"end":642},"obj":"http://edamontology.org/topic_0593"},{"id":"T12","span":{"begin":630,"end":642},"obj":"http://edamontology.org/topic_0593"},{"id":"T13","span":{"begin":1907,"end":1914},"obj":"http://edamontology.org/topic_0078"},{"id":"T14","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/topic_0166"},{"id":"T15","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/topic_2814"},{"id":"T16","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/topic_3538"},{"id":"T17","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/topic_0698"},{"id":"T18","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/topic_0694"},{"id":"T19","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/topic_3542"},{"id":"T20","span":{"begin":1907,"end":1927},"obj":"http://edamontology.org/topic_2826"},{"id":"T21","span":{"begin":1907,"end":1927},"obj":"http://edamontology.org/topic_0143"},{"id":"T22","span":{"begin":1907,"end":1927},"obj":"http://edamontology.org/topic_0736"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":64,"end":74},"obj":"http://edamontology.org/data_0883"},{"id":"T2","span":{"begin":64,"end":83},"obj":"http://edamontology.org/operation_2480"},{"id":"T3","span":{"begin":75,"end":83},"obj":"http://edamontology.org/operation_2945"},{"id":"T4","span":{"begin":507,"end":512},"obj":"http://edamontology.org/operation_3454"},{"id":"T5","span":{"begin":507,"end":512},"obj":"http://edamontology.org/data_2336"},{"id":"T6","span":{"begin":551,"end":561},"obj":"http://edamontology.org/operation_3218"},{"id":"T7","span":{"begin":551,"end":561},"obj":"http://edamontology.org/data_2044"},{"id":"T8","span":{"begin":1102,"end":1112},"obj":"http://edamontology.org/data_0883"},{"id":"T9","span":{"begin":1788,"end":1798},"obj":"http://edamontology.org/data_0883"},{"id":"T10","span":{"begin":1907,"end":1914},"obj":"http://edamontology.org/format_1208"},{"id":"T11","span":{"begin":1907,"end":1914},"obj":"http://edamontology.org/data_1467"},{"id":"T12","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/operation_2488"},{"id":"T13","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/data_1460"},{"id":"T14","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/data_2878"},{"id":"T15","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/operation_0321"},{"id":"T16","span":{"begin":1907,"end":1924},"obj":"http://edamontology.org/data_2992"},{"id":"T17","span":{"begin":1907,"end":1927},"obj":"http://edamontology.org/data_1481"},{"id":"T18","span":{"begin":1907,"end":1927},"obj":"http://edamontology.org/operation_0320"},{"id":"T19","span":{"begin":1907,"end":1927},"obj":"http://edamontology.org/operation_2487"},{"id":"T20","span":{"begin":1915,"end":1924},"obj":"http://edamontology.org/data_0883"},{"id":"T21","span":{"begin":1969,"end":1979},"obj":"http://edamontology.org/operation_0004"},{"id":"T22","span":{"begin":1969,"end":1979},"obj":"http://edamontology.org/operation_2409"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"NGLY1-deficiency","denotations":[{"id":"PD-NGLY1-deficiency-B_T1","span":{"begin":1662,"end":1681},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T2","span":{"begin":2010,"end":2016},"obj":"chem:24139"}],"namespaces":[{"prefix":"hgnc","uri":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:"},{"prefix":"omim","uri":"https://www.omim.org/entry/"},{"prefix":"chem","uri":"https://pubchem.ncbi.nlm.nih.gov/compound/"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"glycoprotein","denotations":[{"id":"glycoprotein_T1","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000728"},{"id":"glycoprotein_T2","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000829"},{"id":"glycoprotein_T3","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004034"},{"id":"glycoprotein_T4","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004176"},{"id":"glycoprotein_T5","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004300"},{"id":"glycoprotein_T6","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0008735"},{"id":"glycoprotein_T7","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0008796"},{"id":"glycoprotein_T8","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0009010"},{"id":"glycoprotein_T9","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0009135"},{"id":"glycoprotein_T10","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0009239"},{"id":"glycoprotein_T11","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0003525"},{"id":"glycoprotein_T12","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004362"},{"id":"glycoprotein_T13","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0006346"},{"id":"glycoprotein_T14","span":{"begin":2036,"end":2064},"obj":"http://purl.uniprot.org/uniprot/Q9BYC5"},{"id":"glycoprotein_T15","span":{"begin":2046,"end":2064},"obj":"http://purl.uniprot.org/uniprot/Q9CA71"},{"id":"glycoprotein_T16","span":{"begin":2046,"end":2064},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001800"},{"id":"glycoprotein_T17","span":{"begin":2046,"end":2064},"obj":"https://acgg.asia/db/gpdb/id/GPDB0005208"},{"id":"glycoprotein_T18","span":{"begin":2046,"end":2064},"obj":"http://purl.uniprot.org/uniprot/F4HZX7"},{"id":"glycoprotein_T19","span":{"begin":2046,"end":2064},"obj":"http://purl.uniprot.org/uniprot/F4IAL1"},{"id":"glycoprotein_T20","span":{"begin":2046,"end":2064},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001924"},{"id":"glycoprotein_T1","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000728"},{"id":"glycoprotein_T2","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0000829"},{"id":"glycoprotein_T3","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004034"},{"id":"glycoprotein_T4","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004176"},{"id":"glycoprotein_T5","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004300"},{"id":"glycoprotein_T6","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0008735"},{"id":"glycoprotein_T7","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0008796"},{"id":"glycoprotein_T8","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0009010"},{"id":"glycoprotein_T9","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0009135"},{"id":"glycoprotein_T10","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0009239"},{"id":"glycoprotein_T11","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0003525"},{"id":"glycoprotein_T12","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0004362"},{"id":"glycoprotein_T13","span":{"begin":1988,"end":2005},"obj":"https://acgg.asia/db/gpdb/id/GPDB0006346"},{"id":"glycoprotein_T14","span":{"begin":2036,"end":2064},"obj":"http://purl.uniprot.org/uniprot/Q9BYC5"},{"id":"glycoprotein_T15","span":{"begin":2046,"end":2064},"obj":"http://purl.uniprot.org/uniprot/Q9CA71"},{"id":"glycoprotein_T16","span":{"begin":2046,"end":2064},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001800"},{"id":"glycoprotein_T17","span":{"begin":2046,"end":2064},"obj":"https://acgg.asia/db/gpdb/id/GPDB0005208"},{"id":"glycoprotein_T18","span":{"begin":2046,"end":2064},"obj":"http://purl.uniprot.org/uniprot/F4HZX7"},{"id":"glycoprotein_T19","span":{"begin":2046,"end":2064},"obj":"http://purl.uniprot.org/uniprot/F4IAL1"},{"id":"glycoprotein_T20","span":{"begin":2046,"end":2064},"obj":"https://acgg.asia/db/gpdb/id/GPDB0001924"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":832,"end":835},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T2","span":{"begin":846,"end":849},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T3","span":{"begin":1027,"end":1030},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T4","span":{"begin":1169,"end":1172},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T5","span":{"begin":1196,"end":1199},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T6","span":{"begin":1297,"end":1300},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T7","span":{"begin":1311,"end":1314},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T8","span":{"begin":1325,"end":1328},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T9","span":{"begin":1339,"end":1342},"obj":"https://acgg.asia/db/lfdb/LfDB0217"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlycoBiology-Epitope","denotations":[{"id":"PD-GlycoEpitope-B_T1","span":{"begin":349,"end":351},"obj":"http://www.glycoepitope.jp/epitopes/AN0785"},{"id":"PD-GlycoEpitope-B_T2","span":{"begin":720,"end":722},"obj":"http://www.glycoepitope.jp/epitopes/AN0785"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T2","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T3","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T4","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T5","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T6","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T7","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T8","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T9","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T10","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T11","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T12","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T13","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T14","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T15","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T16","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T17","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T18","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T19","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T20","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T21","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T22","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T23","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T24","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T25","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T26","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T27","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T28","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T29","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T30","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T31","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T32","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T33","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T34","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T35","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T36","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T37","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T38","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T39","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T40","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T41","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T42","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T43","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T44","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T45","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T46","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T47","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T48","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T49","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T50","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T51","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T52","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T53","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T54","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T55","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T56","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T57","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T58","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T59","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T60","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T61","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T62","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T63","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T64","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T65","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T66","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T67","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T68","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T69","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T70","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T71","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T72","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T73","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T74","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T75","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T76","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T77","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T78","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T79","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T80","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T81","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T82","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T83","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T84","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T85","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T86","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T87","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T88","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T89","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T90","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T91","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T92","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T93","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T94","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T95","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T96","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T97","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T98","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T99","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T100","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T101","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T102","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T103","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T104","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T105","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T106","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T107","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T108","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T109","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T110","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T111","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T112","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T113","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T114","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T115","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T116","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T117","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T118","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T119","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T120","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T121","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T122","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T123","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T124","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T125","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T126","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T127","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T128","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T129","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T130","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T131","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T132","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T133","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T134","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T135","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T136","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T137","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T138","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T139","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T140","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T141","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T142","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T143","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T144","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T145","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T146","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T147","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T148","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T149","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T150","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T151","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T152","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T153","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T154","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T155","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T156","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T157","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T158","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T159","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T160","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T161","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T162","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T163","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T164","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T165","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T166","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T167","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T168","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T169","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T170","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T171","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T172","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T173","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T174","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T175","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T176","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T177","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T178","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T179","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T180","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T181","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T182","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T183","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T184","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T185","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T186","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T187","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T188","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T189","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T190","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T191","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T192","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T193","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T194","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T195","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T196","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T197","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T198","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T199","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T200","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T201","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T202","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T203","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T204","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T205","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T206","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T207","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T208","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T209","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T210","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T211","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T212","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T213","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T214","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T215","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T216","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T217","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T218","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T219","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T220","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T221","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T222","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T223","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T224","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T225","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T226","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T227","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T228","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T229","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T230","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T231","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T232","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T233","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T234","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T235","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T236","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T237","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T238","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T239","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T240","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T241","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T242","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T243","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T244","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T245","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T246","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T247","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T248","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T249","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T250","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T251","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T252","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T253","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T254","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T255","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T256","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T257","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T258","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T259","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T260","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T261","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T262","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T263","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T264","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T265","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T266","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T267","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T268","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T269","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T270","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T271","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T272","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T273","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T274","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T275","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T276","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T277","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T278","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T279","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T280","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T281","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T282","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T283","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T284","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T285","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T286","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T287","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T288","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T289","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T290","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T291","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T292","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T293","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T294","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T295","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T296","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T297","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T298","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T299","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T300","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T301","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T302","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T303","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T304","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T305","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T306","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T307","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T308","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T309","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T310","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T311","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T312","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T313","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T314","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T315","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T316","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T317","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T318","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T319","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T320","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T321","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T322","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T323","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T324","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T325","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T326","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T327","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T328","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T329","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T330","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T331","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T332","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T333","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T334","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T335","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T336","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T337","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T338","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T339","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T340","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T341","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T342","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T343","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T344","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T345","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T346","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T347","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T348","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T349","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T350","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T351","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T352","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T353","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T354","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T355","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T356","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T357","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T358","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T359","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T360","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T361","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T362","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T363","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T364","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T365","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T366","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T367","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T368","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T369","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T370","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T371","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T372","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T373","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T374","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T375","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T376","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T377","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T378","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T379","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T380","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T381","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T382","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T383","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T384","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T385","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T386","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T387","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T388","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T389","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T390","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T391","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T392","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T393","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T394","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T395","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T396","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T397","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T398","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T399","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T400","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T401","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T402","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T403","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T404","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T405","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T406","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T407","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T408","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T409","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T410","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T411","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T412","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T413","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T414","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T415","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T416","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T417","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T418","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T419","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T420","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T421","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T422","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T423","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T424","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T425","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T426","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T427","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T428","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T429","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T430","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T431","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T432","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T433","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T434","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T435","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T436","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T437","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T438","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T439","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T440","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T441","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T442","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T443","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T444","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T445","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T446","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T447","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T448","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T449","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T450","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T451","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T452","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T453","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T454","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T455","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T456","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T457","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T458","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T459","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T460","span":{"begin":832,"end":835},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T461","span":{"begin":846,"end":849},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T462","span":{"begin":1027,"end":1030},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T463","span":{"begin":1169,"end":1172},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T464","span":{"begin":1196,"end":1199},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T465","span":{"begin":1297,"end":1300},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T466","span":{"begin":1311,"end":1314},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T467","span":{"begin":1325,"end":1328},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T468","span":{"begin":1339,"end":1342},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""},{"id":"GlycanIUPAC_T469","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T470","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T471","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T472","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T473","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T474","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T475","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T476","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T477","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T478","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T479","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T480","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T481","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T482","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T483","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T484","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T485","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T486","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T487","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T488","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T489","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T490","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T491","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T492","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T493","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T494","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T495","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T496","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T497","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T498","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T499","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T500","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T501","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T502","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T503","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T504","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T505","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T506","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T507","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T508","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T509","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T510","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T511","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T512","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T513","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T514","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T515","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T516","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T517","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T518","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T519","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T520","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T521","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T522","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T523","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T524","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T525","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T526","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T527","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T528","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T529","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T530","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T531","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T532","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T533","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T534","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T535","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T536","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T537","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T538","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T539","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T540","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T541","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T542","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T543","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T544","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T545","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T546","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T547","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T548","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T549","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T550","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T551","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T552","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T553","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T554","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T555","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T556","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T557","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T558","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T559","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T560","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T561","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T562","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T563","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T564","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T565","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T566","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T567","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T568","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T569","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T570","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T571","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T572","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T573","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T574","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T575","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T576","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T577","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T578","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T579","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T580","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T581","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T582","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T583","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T584","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T585","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T586","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T587","span":{"begin":986,"end":989},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""},{"id":"GlycanIUPAC_T588","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T589","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T590","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T591","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T592","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T593","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T594","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T595","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T596","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T597","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T598","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T599","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T600","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T601","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T602","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T603","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T604","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T605","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T606","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T607","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T608","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T609","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T610","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T611","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T612","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T613","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T614","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T615","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T616","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T617","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T618","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T619","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T620","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T621","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T622","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T623","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T624","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T625","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T626","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T627","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T628","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T629","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T630","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T631","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T632","span":{"begin":2010,"end":2016},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":39,"end":48},"obj":"http://purl.obolibrary.org/obo/UBERON_0003124"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":258,"end":267},"obj":"http://purl.obolibrary.org/obo/UBERON_0003124"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":776,"end":781},"obj":"Glycan"},{"id":"T2","span":{"begin":914,"end":919},"obj":"Glycan"},{"id":"T3","span":{"begin":970,"end":975},"obj":"Glycan"},{"id":"T4","span":{"begin":1113,"end":1118},"obj":"Glycan"},{"id":"T5","span":{"begin":1241,"end":1246},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A6","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A7","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A8","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A9","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A5","pred":"glycosmos_id","subj":"T5","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A10","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":776,"end":781},"obj":"Glycan"},{"id":"T2","span":{"begin":914,"end":919},"obj":"Glycan"},{"id":"T3","span":{"begin":970,"end":975},"obj":"Glycan"},{"id":"T4","span":{"begin":1113,"end":1118},"obj":"Glycan"},{"id":"T5","span":{"begin":1241,"end":1246},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A6","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A7","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A8","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A9","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"},{"id":"A5","pred":"glycosmos_id","subj":"T5","obj":"https://glycosmos.org/glycans/show/G76685HR"},{"id":"A10","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos15-Taxon","denotations":[{"id":"T1","span":{"begin":33,"end":38},"obj":"Organism"},{"id":"T2","span":{"begin":252,"end":257},"obj":"Organism"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":1963,"end":1968},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/GO_0005794"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":149},"obj":"Sentence"},{"id":"T2","span":{"begin":150,"end":472},"obj":"Sentence"},{"id":"T3","span":{"begin":473,"end":643},"obj":"Sentence"},{"id":"T4","span":{"begin":644,"end":1724},"obj":"Sentence"},{"id":"T5","span":{"begin":1725,"end":2065},"obj":"Sentence"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"GlyCosmos15-FMA","denotations":[{"id":"T1","span":{"begin":39,"end":48},"obj":"Body_part"},{"id":"T2","span":{"begin":258,"end":267},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"FMA:80224"},{"id":"A2","pred":"db_id","subj":"T2","obj":"FMA:80224"}],"namespaces":[{"prefix":"FMA","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":33,"end":38},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":252,"end":257},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":1963,"end":1968},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/GO_0005794"}],"text":"Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.\nGlycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively. Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy. The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of hCG alpha comprised monosialylated 'monoantenary' NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-4'), disialylated diantennary NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[NeuAc alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and NeuAc alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of hCG alpha carried N2 and N1-4' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of hCG beta contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the N-acetylglucosamine linked to Asn-13 and Asn-30, respectively. The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase."}